Necrotizing soft tissue infections (NSTI) have been recognized for millennia and continue to impose considerable burden on both patient and society in terms of morbidity, death, and the allocation of resources. With improvements in the delivery of critical care, outcomes have improved, although disease-specific therapies are lacking. The basic principles of early diagnosis, of prompt and broad antimicrobial therapy, and of aggressive debridement have remained unchanged. Clearly novel and new therapeutics are needed to combat this persistently lethal disease. This review emphasizes the pillars of NSTI management and then summarizes the contemporary evidence supporting the incorporation of novel adjuncts to the pharmacologic and operative foundations of managing this disease.
Get full access to this article
View all access options for this article.
References
1.
DescampsV, AitkenJ, LeeMG. Hippocrates on necrotising fasciitis. Lancet, 1994; 344:556.
2.
MurphySC. The person behind the eponym: Wilhelm Frederick von Ludwig [1790–1865]. J Oral Pathol Med, 1996; 25:513–515.
3.
BaurieeneH. Sur Une Plaie Contuse qui s'est terminee par la sphacele de la scrotum. J Med Chir Pharm, 1764; 20:251–256.
4.
FournierJA. Gangrene Foudroyante de la verge. Med Pract, 1883; 4:589–597.
5.
FournierJA. Etude clinique de la gangrene foudroyante de la verge. Semaine Med, 1884; 4:69.
6.
JonesJ. Surgical memoirs of the war of the rebellion: Investigation upon the nature, causes, and treatment of hospital gangrene as prevailed in the Confederate armies 1861–1865. New York: U.S. Sanitary Commission; 1871.
7.
WilsonB. Necrotizing fasciitis. Am Surg, 1952; 18:416–431.
8.
PsoinosCM, FlahiveJM, ShawJJ, et al.Contemporary trends in necrotizing soft-tissue infections in the United States. Surgery, 2013; 153:819–827.
9.
MayAK, StaffordRE, BulgerEM, et al.Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt), 2009; 10:467–499.
10.
StevensDL, BisnoAL, ChambersHF, et al.Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis, 2014; 59:e10–e52.
11.
StevensDL, BisnoAL, ChambersHF, et al.Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis, 2014; 59:147–159.
12.
HakkarainenTW, KopariNM, PhamTN, EvansHL. Necrotizing soft tissue infections: Review and current concepts in treatment, systems of care, and outcomes. Curr Probl Surg, 2014; 51:344–362.
13.
BuccaK, SpencerR, OrfordN, et al.Early diagnosis and treatment of necrotizing fasciitis can improve survival: An observational intensive care unit cohort study. ANZ J Surg, 2013; 83:365–370.
14.
WongCH, ChangHC, PasupathyS, et al.Necrotizing fasciitis: Clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am, 2003; 85-A:1454–1460.
15.
AnayaDA, McMahonK, NathensAB, et al.Predictors of mortality and limb loss in necrotizing soft tissue infections. Arch Surg, 2005; 140:151–157.
GuyattGH, OxmanAD, KunzR, et al.Going from evidence to recommendations. BMJ, 2008; 336:1049–1051.
18.
GuyattGH, OxmanAD, KunzR, et al.What is “quality of evidence” and why is it important to clinicians?. BMJ, 2008; 336:995–998.
19.
GuyattGH, OxmanAD, VistGE, et al.GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008; 336:924–926.
20.
JaeschkeR, GuyattGH, DellingerP, et al.Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ, 2008; 337:a744.
Ellis SimonsenSM, van OrmanER, HatchBE, et al.Cellulitis incidence in a defined population. Epidemiol Infect, 2006; 134:293–299.
23.
EndorfFW, KleinMB, MackCD, et al.Necrotizing soft-tissue infections: Differences in patients treated at burn centers and non-burn centers. J Burn Care Res, 2008; 29:933–938.
24.
GeorgeSM, HarrisonDA, WelchCA, et al.Dermatological conditions in intensive care: A secondary analysis of the Intensive Care National Audit and Research Centre (ICNARC) Case Mix Programme database. Crit Care, 2008; 12(Suppl 1):S1.
25.
GunterOL, GuillamondeguiOD, MayAK, DiazJJ. Outcome of necrotizing skin and soft tissue infections. Surg Infect [Larchmt], 2008; 9:443–450.
26.
MayAK. Skin and soft tissue infections. Surg Clin North Am, 2009; 89:403–420.
27.
MillsMK, FaraklasI, DavisC, et al.Outcomes from treatment of necrotizing soft-tissue infections: Results from the National Surgical Quality Improvement Program database. Am J Surg, 2010; 200:790–796.
28.
KaoLS, LewDF, ArabSN, et al.Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: A multicenter study. Am J Surg, 2011; 202:139–145.
29.
SaraniB, StrongM, PascualJ, SchwabCW. Necrotizing fasciitis: Current concepts and review of the literature. J Am Coll Surg, 2009; 208:279–288.
30.
NapolitanoLM. Severe soft tissue infections. Infect Dis Clin North Am, 2009; 23:571–591.
31.
ElliottD, KuferaJA, MyersRA. The microbiology of necrotizing soft tissue infections. Am J Surg, 2000; 179:361–366.
32.
FreischlagJA, AjalatG, BusuttilRW. Treatment of necrotizing soft tissue infections. The need for a new approach. Am J Surg, 1985; 149:751–755.
33.
PiedraT, Martin-CuestaL, ArnaizJ, et al.Necrotizing fasciitis secondary to diverticulitis. Emerg Radiol, 2007; 13:345–348.
34.
LiuSY, NgSS, LeeJF. Multi-limb necrotizing fasciitis in a patient with rectal cancer. World J Gastroenterol, 2006; 12:5256–5258.
35.
ChildersBJ, PotyondyLD, NachreinerR, et al.Necrotizing fasciitis: A fourteen-year retrospective study of 163 consecutive patients. Am Surg, 2002; 68:109–116.
SpitalnicSJ, SucovA. Ludwig's angina: Case report and review. J Emerg Med, 1995; 13:499–503.
38.
SaifeldeenK, EvansR. Ludwig's angina. Emerg Med J, 2004; 21:242–243.
39.
QuinnFBJr. Ludwig angina. Arch Otolaryngol Head Neck Surg, 1999; 125:599.
40.
DarenbergJ, Luca-HarariB, JasirA, et al.Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis, 2007; 45:450–458.
41.
ChelsomJ, HalstensenA, HagaT, HoibyEA. Necrotising fasciitis due to group A streptococci in western Norway: Incidence and clinical features. Lancet, 1994; 344:1111–1115.
EneliI, DaviesHD. Epidemiology and outcome of necrotizing fasciitis in children: An active surveillance study of the Canadian Paediatric Surveillance Program. J Pediatr, 2007; 151:79–84.
44.
YoungLM, PriceCS. Community-acquired methicillin-resistant Staphylococcus aureus emerging as an important cause of necrotizing fasciitis. Surg Infect (Larchmt), 2008; 9:469–474.
45.
WallinTR, HernHG, FrazeeBW. Community-associated methicillin-resistant Staphylococcus aureus. Emerg Med Clin North Am, 2008; 26:431–455.
46.
BrettMM, HoodJ, BrazierJS, et al.Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. Epidemiol Infect, 2005; 133:575–582.
47.
KimuraAC, HigaJI, LevinRM, et al.Outbreak of necrotizing fasciitis due to Clostridium sordellii among black-tar heroin users. Clin Infect Dis, 2004; 38:e87–e91.
48.
StevensDL, BryantAE. Pathogenesis of Clostridium perfringens infection: Mechanisms and mediators of shock. Clin Infect Dis, 1997; 25(Suppl 2):S160–S164.
KoWC, LeeHC, ChuangYC, et al.Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia. J Infect, 2000; 40:267–273.
52.
TsaiYH, HsuRW, HuangTJ, et al.Necrotizing soft-tissue infections and sepsis caused by Vibrio vulnificus compared with those caused by Aeromonas species. J Bone Joint Surg Am, 2007; 89:631–636.
53.
GoldWL, SalitIE. Aeromonas hydrophila infections of skin and soft tissue: Report of 11 cases and review. Clin Infect Dis, 1993; 16:69–74.
TsaiYH, HsuRW, HuangKC, et al.Systemic Vibrio infection presenting as necrotizing fasciitis and sepsis. A series of thirteen cases. J Bone Joint Surg Am, 2004; 86-A:2497–2502.
LoseeJE, SelberJ, VegaS, et al.Primary cutaneous mucormycosis: Guide to surgical management. Ann Plast Surg, 2002; 49:385–390.
62.
BoelaertJR, de LochtM, Van CutsemJ, et al.Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest, 1993; 91:1979–1986.
63.
GreenbergRN, ScottLJ, VaughnHH, RibesJA. Zygomycosis (mucormycosis): Emerging clinical importance and new treatments. Curr Opin Infect Dis, 2004; 17:517–525.
64.
MajeskiJA, AlexanderJW. Early diagnosis, nutritional support, and immediate extensive debridement improve survival in necrotizing fasciitis. Am J Surg, 1983; 145:784–787.
65.
McHenryCR, PiotrowskiJJ, PetrinicD, MalangoniMA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg, 1995; 221:558–563.
66.
StevensDL, TannerMH, WinshipJ, et al.Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med, 1989; 321:1–7.
67.
StoneHH, MartinJDJr. Synergistic necrotizing cellulitis. Ann Surg, 1972; 175:702–711.
68.
MajeskiJA, JohnJFJr. Necrotizing soft tissue infections: A guide to early diagnosis and initial therapy. South Med J, 2003; 96:900–905.
ElliottDC, KuferaJA, MyersRA. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg, 1996; 224:672–683.
71.
BangsbergDR, RosenJI, AragonT, et al.Clostridial myonecrosis cluster among injection drug users: A molecular epidemiology investigation. Arch Intern Med, 2002; 162:517–522.
72.
McGuiganCC, PenriceGM, GruerL, et al.Lethal outbreak of infection with Clostridium novyi type A and other spore-forming organisms in Scottish injecting drug users. J Med Microbiol, 2002; 51:971–977.
73.
Ben-AbrahamR, KellerN, VeredR, et al.Invasive group A streptococcal infections in a large tertiary center: Epidemiology, characteristics and outcome. Infection, 2002; 30:81–85.
LilleST, SatoTT, EngravLH, et al.Necrotizing soft tissue infections: Obstacles in diagnosis. J Am Coll Surg, 1996; 182:7–11.
76.
ForbesN, RankinAP. Necrotizing fasciitis and non steroidal anti-inflammatory drugs: A case series and review of the literature. N Z Med J, 2001; 114:3–6.
77.
KahnLH, StyrtBA. Necrotizing soft tissue infections reported with nonsteroidal antiinflammatory drugs. Ann Pharmacother, 1997; 31:1034–1039.
78.
StevensDL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome?. Clin Infect Dis, 1995; 21:977–980.
79.
WongCH, KhinLW, HengKS, et al.The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: A tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med, 2004; 32:1535–1541.
80.
SuYC, ChenHW, HongYC, et al.Laboratory risk indicator for necrotizing fasciitis score and the outcomes. ANZ J Surg, 2008; 78:968–972.
81.
HollandMJ. Application of the Laboratory Risk Indicator in Necrotising Fasciitis (LRINEC) score to patients in a tropical tertiary referral centre. Anaesth Intensive Care, 2009; 37:588–592.
82.
WallDB, de VirgilioC, BlackS, KleinSR. Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infection. Am J Surg, 2000; 179:17–21.
83.
BrothersTE, TaggeDU, StutleyJE, et al.Magnetic resonance imaging differentiates between necrotizing and non-necrotizing fasciitis of the lower extremity. J Am Coll Surg, 1998; 187:416–421.
84.
MajeskiJ, MajeskiE. Necrotizing fasciitis: Improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J, 1997; 90:1065–1068.
85.
LeePC, TurnidgeJ, McDonaldPJ. Fine-needle aspiration biopsy in diagnosis of soft tissue infections. J Clin Microbiol, 1985; 22:80–83.
86.
StevensDL, BryantAE, YanS. Invasive group A streptococcal infection: New concepts in antibiotic treatment. Int J Antimicrob Agents, 1994; 4:297–301.
87.
StevensDL, MaY, SalmiDB, et al.Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis, 2007; 195:202–211.
88.
AwadSS, ElhabashSI, LeeL, et al.Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: Reconsideration of empiric antimicrobial therapy. Am J Surg, 2007; 194:606–610.
89.
HidayatLK, HsuDI, QuistR, et al.High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med, 2006; 166:2138–2144.
90.
HowdenBP, WardPB, CharlesPG, et al.Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis, 2004; 38:521–528.
91.
Del PoetaM, SchellWA, PerfectJR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother, 1997; 41:1835–1836.
92.
Espinel-IngroffA. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol, 1998; 36:2950–2956.
93.
PfallerMA, MarcoF, MesserSA, JonesRN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis, 1998; 30:251–255.
94.
SpanakisEK, AperisG, MylonakisE. New agents for the treatment of fungal infections: Clinical efficacy and gaps in coverage. Clin Infect Dis, 2006; 43:1060–1068.
95.
SunQN, FothergillAW, McCarthyDI, et al.In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother, 2002; 46:1581–1582.
96.
van BurikJA, HareRS, SolomonHF, et al.Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis, 2006; 42:e61–e65.
ParkashS, GajendranV. Surgical reconstruction of the sequelae of penile and scrotal gangrene: A plea for simplicity. Br J Plast Surg, 1984; 37:354–357.
99.
TaguchiH. More than 10 years of experience with reconstructed scrotums. J Urol, 1976; 116:469–471.
100.
MaguinaP, PalmieriTL, GreenhalghDG. Split thickness skin grafting for recreation of the scrotum following Fournier's gangrene. Burns, 2003; 29:857–862.
101.
VincentMP, HortonCE, DevineCJJr. An evaluation of skin grafts for reconstruction of the penis and scrotum. Clin Plast Surg, 1988; 15:411–424.
AyanF, SunamakO, PaksoySM, et al.Fournier's gangrene: A retrospective clinical study on forty-one patients. ANZ J Surg, 2005; 75:1055–1058.
106.
MindrupSR, KealeyGP, FallonB. Hyperbaric oxygen for the treatment of fournier's gangrene. J Urol, 2005; 173:1975–1977.
107.
ShawJJ, PsoinosC, EmhoffTA, et al.Not just full of hot air: Hyperbaric oxygen therapy increases survival in cases of necrotizing soft tissue infections. Surg Infect (Larchmt), 2014; 15:328–335.
108.
WilkinsonD, DooletteD. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg, 2004; 139:1339–1345.
109.
GeorgeME, RuethNM, SkardaDE, et al.Hyperbaric oxygen does not improve outcome in patients with necrotizing soft tissue infection. Surg Infect (Larchmt), 2009; 10:21–28.
110.
MehlAA, Nogueira FilhoDC, MantovaniLM, et al.Management of Fournier's gangrene: Experience of a university hospital of Curitiba. Rev Col Bras Cir, 2010; 37:435–441.
111.
LiCQ, GersonS, SnyderB. Case report: Hyperbaric oxygen and MRI findings in radiation-induced optic neuropathy. Undersea Hyperb Med, 2014; 41:59–63.
112.
SugiharaA, WatanabeH, OohashiM, et al.The effect of hyperbaric oxygen therapy on the bout of treatment for soft tissue infections. J Infect, 2004; 48:330–333.
113.
MasseyPR, SakranJV, MillsAM, et al.Hyperbaric oxygen therapy in necrotizing soft tissue infections. J Surg Res, 2012; 177:146–151.
114.
HassanZ, MullinsRF, FriedmanBC, et al.Treating necrotizing fasciitis with or without hyperbaric oxygen therapy. Undersea Hyperb Med, 2010; 37:115–123.
115.
KrenkL, NielsenHU, ChristensenME. Necrotizing fasciitis in the head and neck region: An analysis of standard treatment effectiveness. Eur Arch Otorhinolaryngol, 2007; 264:917–922.
116.
WolfH, RusanM, LambertsenK, OvesenT. Necrotizing fasciitis of the head and neck. Head Neck, 2010; 32:1592–1596.
117.
HampsonN, AtikD. Central nervous system oxygen toxicity during routine hyperbaric oxygen therapy. Undersea Hyperb Med, 2003; 30:147–153.
118.
PlafkiC, PetersP, AlmelingM, et al.Complications and side effects of hyperbaric oxygen therapy. Aviat Space Environ Med, 2000; 71:119–124.
119.
Norrby-TeglundA, BasmaH, AnderssonJ, et al.Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: Implications for therapeutic efficacy. Clin Infect Dis, 1998; 26:631–638.
120.
Norrby-TeglundA, KaulR, LowDE, et al.Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol, 1996; 156:3057–3064.
121.
DantalJ. Intravenous immunoglobulins: In-depth review of excipients and acute kidney injury risk. Am J Nephrol, 2013; 38:275–284.
122.
WerdanK, PilzG, BujdosoO, et al.Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med, 2007; 35:2693–2701.
123.
DarenbergJ, IhendyaneN, SjolinJ, et al.Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis, 2003; 37:333–340.
124.
KaulR, McGeerA, Norrby-TeglundA, et al.Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis, 1999; 28:800–807.
125.
Norrby-TeglundA, IhendyaneN, DarenbergJ. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis, 2003; 35:683–689.
126.
AlejandriaMM, LansangMA, DansLF, MantaringJB, 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev, 2013; 9:CD001090.
127.
LauplandKB, KirkpatrickAW, DelaneyA. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis. Crit Care Med. 2007; 35:2686–2692.
128.
KreymannKG, de HeerG, NierhausA, KlugeS. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med, 2007; 35:2677–2685.
129.
TurgeonAF, HuttonB, FergussonDA, et al.Meta-analysis: Intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med, 2007; 146:193–203.
130.
NeilsonAR, BurchardiH, SchneiderH. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care, 2005; 20:239–249.
131.
PildalJ, GotzschePC. Polyclonal immunoglobulin for treatment of bacterial sepsis: A systematic review. Clin Infect Dis, 2004; 39:38–46.
132.
HamanoN, NishiK, OnoseA, et al.Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock. J Intensive Care, 2013; 1:4.
133.
RodriguezA, RelloJ, NeiraJ, et al.Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock, 2005; 23:298–304.
134.
TugrulS, OzcanPE, AkinciO, et al.The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis (ISRCTN28863830). Crit Care, 2002; 6:357–362.
135.
TagamiT, MatsuiH, FushimiK, YasunagaH. Intravenous immunoglobulin use in septic shock patients after emergency laparotomy. J Infect, 2015; 71:158–166.
136.
TagamiT, MatsuiH, FushimiK, YasunagaH. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: An observational nationwide study. Clin Infect Dis, 2015; 61:385–392.
137.
CavazzutiI, SerafiniG, BusaniS, et al.Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med, 2014; 40:1888–1896.
138.
YavuzL, AynaliG, AynaliA, et al.The effects of adjuvant immunoglobulin M-enriched immunoglobulin therapy on mortality rate and renal function in sepsis-induced multiple organ dysfunction syndrome: Retrospective analysis of intensive care unit patients. J Int Med Res, 2012; 40:1166–1174.
139.
BerlotG, VassalloMC, BusettoN, et al.Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: A retrospective analysis. J Crit Care, 2012; 27:167–171.
140.
BudaS, RiefoloA, BiscioneR, et al.Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery. J Cardiothorac Vasc Anesth, 2005; 19:440–445.
141.
MehtaS, McGeerA, LowDE, et al.Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU. Chest, 2006; 130:1679–1686.
142.
LinnerA, DarenbergJ, SjolinJ, et al.Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: A comparative observational study. Clin Infect Dis, 2014; 59:851–857.
143.
Prevention Centers for Disease Control and Prevention.. Streptococcal toxic shock syndrome (STSS) (Streptococcus pyogenese) 2010 Case Definition. Atlanta, GA: CDC, 2010.
144.
ZhouF, PengZ, MuruganR, KellumJA. Blood purification and mortality in sepsis: A meta-analysis of randomized trials. Crit Care Med, 2013; 41:2209–2220.
145.
RimmerE, HoustonBL, KumarA, et al.The efficacy and safety of plasma exchange in patients with sepsis and septic shock: A systematic review and meta-analysis. Crit Care, 2014; 18:699.
146.
BorthwickEM, HillCJ, RabindranathKS, et al.High-volume haemofiltration for sepsis. Cochrane Database Syst Rev, 2013; 1:CD008075.
147.
CruzDN, AntonelliM, FumagalliR, et al.Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial. JAMA, 2009; 301:2445–2452.
148.
NemotoH, NakamotoH, OkadaH, et al.Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif, 2001; 19:361–368.
149.
LivigniS, BertoliniG, RossiC, et al.Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial. BMJ Open, 2014; 4:e003536.
150.
PayenD, MateoJ, CavaillonJM, et al.Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: A randomized controlled trial. Crit Care Med, 2009; 37:803–810.
151.
VincentJL, LaterrePF, CohenJ, et al.A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock, 2005; 23:400–405.
152.
PengY, YuanZ, LiH. Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis. Burns, 2005; 31:623–628.
153.
NakamuraT, KawagoeY, MatsudaT, et al.Effect of polymyxin B-immobilized fiber on blood metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in acute respiratory distress syndrome patients. Blood Purif, 2004; 22:256–260.
154.
ReinhartK, Meier-HellmannA, BealeR, et al.Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis. Crit Care Med, 2004; 32:1662–1668.
155.
NakamuraT, UshiyamaC, SuzukiY, et al.Hemoperfusion with polymyxin B-immobilized fiber in septic patients with methicillin-resistant Staphylococcus aureus-associated glomerulonephritis. Nephron Clin Pract, 2003; 94:c33–c39.
156.
NakamuraT, UshiyamaC, SuzukiY, et al.Hemoperfusion with polymyxin B immobilized fibers for urinary albumin excretion in septic patients with trauma. ASAIO J, 2002; 48:244–248.
157.
ColeL, BellomoR, HartG, et al.A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med, 2002; 30:100–106.
158.
BusundR, KouklineV, UtrobinU, NedashkovskyE. Plasmapheresis in severe sepsis and septic shock: A prospective, randomised, controlled trial. Intensive Care Med, 2002; 28:1434–1439.
159.
ReevesJH, ButtWW, ShannF, et al.Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med, 1999; 27:2096–2104.
160.
ZuH, LiQ, HuangP, WangX. Therapeutic value of blood purification and prognostic utilities of early serum procalcitonin, C reactive protein, and brain natriuretic peptide levels in severely burned patients with sepsis. Cell Biochem Biophys, 2015; 72:259–263.
161.
NakamuraT, UshiyamaC, SuzukiY, et al.Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus. J Hosp Infect, 2003; 53:58–63.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
